Multicenter study on the Pharmacokinetics and pharmacogenetics of crizotinib in patients with ALK fusion gene positive NSCLC
Phase of Trial: Phase IV
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.
- 09 Sep 2015 Status changed from active, no longer recruiting to completed, as reported at the 16th World Conference on Lung Cancer.
- 12 Feb 2013 New trial record